Food and beverages interact with certain psychiatric medications to alter their pharmacokinetic properties, resulting in potentially unintended health outcomes. In this podcast episode, Dr. Rajnish Mago describes common food and beverages that interact with psychiatric medication and provides recommendations for avoiding unintended food-drug interactions.

Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.

 Learning Objectives: After completing this educational activity, you should be better able to:

• Describe the effects of food on the bioavailability of certain psychotropic medications Discuss current evidence of the brain-gut connection’s impact on mental health

• Describe the effects of vitamin C, caffeine, and grapefruit on the pharmacokinetics of certain psychotropic medications

 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.

 Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.

 Peer Review: The content was peer-reviewed by a PharmD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

 Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

 Faculty Interviewer / Author

Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris  

Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris

Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris

Faculty Interviewee / Author

Rajnish Mago, MD

Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Travel Expenses: Intas Pharmaceuticals (for Indian Psychiatric Association annual meeting)

Stockholder: Johnson and Johnson

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

 The Planning Committee and Peer Reviewer have no financial relationships to disclose.

 Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

 Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.

 Support: This activity is supported solely by the provider, NEI.

 Released: May 11, 2020          CME credit expires: May 11, 2023